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Cholera: A Continuing Public
Health Threat
The emergence of cholera in Haiti
highlighted the difficulties in containing
cholera outbreaks with only safe water,
sanitation, hygiene, and appropriate case
management. In less developed settings
where cholera occurs, these basic needs
are often not met or are rapidly over-
whelmed during man-made or natural
disasters. Prior to the Haitian outbreak,
countries in Africa and Asia had borne
most of the cholera burden, with an
estimated 1.4 billion people at risk, 2.8
million cases, and 100,000 to 200,000
deaths occurring annually [1,2]; however,
because of difficulties in surveillance and
differences in reporting systems, only
245,393 cases with 3,034 deaths were
reported to the World Health Organiza-
tion (WHO) in 2012 [1]. This figure does
not include the large number of acute
watery diarrhoea cases reported in Asia, of
which a significant proportion is caused by
Vibrio cholerae. As cholera continues to be
a global public health problem, in 2011,
the World Health Assembly called for an
integrated and comprehensive approach
to cholera control, including oral cholera
vaccines (OCVs) [3].
OCVs have been available for more
than 20 years, but public health use has
been limited. Vietnam is the first and
currently the only country in the world to
use killed OCVs routinely in its public
health program. This article describes the
cholera problem in Vietnam and how an
oral cholera vaccine was developed and
used as a component of a public health
strategy against the disease.
Cholera in Vietnam
Cholera has been endemic in Vietnam
since 1964, when V. cholerae O1 El Tor
was first identified in the country. Vietnam
uses the term ‘‘severe watery diarrhoea’’
for culture-confirmed cases of cholera or
clinically diagnosed cholera during an
outbreak. Reports of cholera are forward-
ed to and collated by the Epidemiology
Unit of the National Institute of Hygiene
and Epidemiology (NIHE) under the
Ministry of Health (see Text S1 and Table
S1).
From 1991 to 2001, reported cases of
severe watery diarrhoea were highest in
the South Central Coast, followed by the
North Central Coast. During the same
period, Hue province in the North Central
Coast had the highest annual incidence
rate of severe watery diarrhoea cases, with
the majority of cases coming from its
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Summary Points
N Vietnam is the first and only country in the world to regularly use oral cholera
vaccines (OCVs) in their cholera control program.
N From 1998 to 2012, more than 10.9 million doses of the locally produced OCV
were deployed in the country through its public health system.
N We present an overview of cholera epidemiology in Vietnam and the
development and deployment of the OCV.
N Since 1997, the number of cholera cases in Vietnam has declined, in association
with increased OCV use as well as improvements in socioeconomic and water
and sanitation conditions. It is not possible to establish the relative
contributions of each of these to the reduction in cholera rates.
N Hue, the only province to use OCVs consistently every year, has not reported
any cholera case since 2003.
N As WHO organizes a stockpile of OCV for use in emergencies and recommends
the use of OCVs together with traditional means of control, the experience in
Vietnam will be helpful to other at-risk countries as they look towards adopting
the vaccine in their cholera control programs.
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capital, Hue city (NIHE, unpublished). In
a review of cholera epidemiology in
Vietnam from 1991 to 2001 by Kelly-
Hope et al., the average annual incidence
for the whole country was 2.7 cases per
100,000 people [4].
From 1992 to 1995, 2,500 to 6,000
cases were reported annually [5]; however,
since 1997, a decline in the number of
cases has been seen, including a 10-fold
drop between 1996 and 1997. While this
decrease may have been initially explained
by the cyclical nature of the disease, the
decline was sustained. From 1998 to 2006,
the number of cases ranged from 0 to 343
annually, mostly in the southern provinces
of An Giang, Ca Mau, and Dong Thap
and the central provinces of Quang Tri
and Hue (Figure 1). Between 1998 and
2002, only one other case was seen in
Hue, until October 2003 when an out-
break with 200 cases was reported.
In October 2007, an increase in the
number of cases was seen in Hanoi,
subsequently affecting nearby provinces
in the North. 1,907 and 886 cases were
reported in 2007 and 2008, respectively.
This outbreak in Hanoi was unusual
because of the large number of cases that
lasted through the winter season. Between
1998 and 2012, case numbers varied
between 0 and 1,907 per annum, with
an estimated annual incidence of 0 to 2.24
cases per 100,000 people (median 0.03
and mean 0.28) (Figure 2). The majority
of the cholera cases were reported from
the northern region during the 2007–2010
outbreaks.
The history of the development of
oral cholera vaccine in Vietnam is
shown in Table 1. The evolution in the
formulation of the Vietnamese vaccine
and how it is administered is shown in
Table S2.
Policy and Practice of Oral
Cholera Vaccination in Vietnam
On 19 August 1997, the Vietnamese
government issued a directive including
OCVs in the National Expanded Pro-
gramme on Immunization (EPI) schedule
in areas at risk for cholera. In the EPI
schedule, two doses of OCV are to be
provided two weeks apart to children two
to five years of age; however, local health
policy makers may decide on the age
groups included for vaccination depending
on the local epidemiology, the number of
vaccine doses available, and the capability
of local government to support the vacci-
nation.
From 1998 to 2012, more than 10.9
million doses of OCV were deployed in 16
provinces and major cities through Viet-
nam’s EPI. Of these doses, 78% were
procured from 1998 to 2006 (Figure 2)
and were primarily used in the central and
southern provinces where the incidence of
cholera was higher. Figure 1 shows the
provinces where OCVs were deployed. In
addition, approximately 3 million doses
were purchased from Vabiotech by the
Ministry of Health (specifically during the
2007–2008 cholera outbreak), by the
Asian Development Bank and by the
private sector. Among the 16 provinces
that have deployed OCVs, one province,
the central coastal province of Hue,
consistently used OCVs annually since
1998, providing more than 2.14 million
doses to its inhabitants, or two doses of
OCV per inhabitant (using 2010 popula-
tion). Deployment of vaccines was made
per commune, the lowest administrative
unit.
In most provinces, vaccination targeted
children aged two to five years. However,
in Hue, all non-pregnant residents of
communes aged two years and older were
vaccinated every three to five years [6]
depending on the local cholera epidemi-
ology or occurrence of flooding. After the
2003 cholera outbreak in Hue, the pro-
vincial government provided vaccines to
all eligible residents of the seven districts in
a phased manner between 2004 and 2007.
No cases were detected in Hue since 2003.
After Hue, Ca Mau province deployed
the second highest number of vaccine
doses, mostly in 2000–2001 and 2003–
2006. In most years, Ca Mau provided
vaccines to children aged two to five
years. However, in 2001, 234 children at
a primary school (aged five to 12 years
old) in Ca Mau City received OCVs
when the local health authorities deter-
mined that these children were at risk for
cholera [7].
Quang Tri province, located just north
of Hue near the Laotian border, immu-
nized children aged two to five years from
2000 to 2007 (except in 2003) in com-
munes perceived to be at risk. Cholera was
reported in 1999 and 2000, then again in
2003. Because of its proximity to the
border, OCVs were deployed when cases
were reported in nearby Laos. Outbreaks
of cholera were reported in Laos in 1994
to 1996 and then again in 1998 to 2002
[8]. No cholera case was reported in
Quang Tri after 2004, despite the reported
cholera outbreak in Laos in 2007 [9].
From 1998–2005, OCVs were deployed
in select communes in An Giang province
in the South for five years, where cholera
was reported in five of the seven years.
Cholera reappeared in An Giang in 2010,
after five years of absence from 2005–
2009, and OCVs were again deployed in
2011.
Cholera vaccines were used in areas
with the highest number of cholera cases
(Figure 1). Apart from Hue, An Giang and
Ca Mau had the highest number of cases
from 1998 to 2004 at 154 and 93 cases,
respectively, during these years. However,
apart from Hanoi, provinces that were
hard-hit during the 2007–2008 outbreaks
did not request nor did they deploy OCVs.
Decision Making to Procurement
In the EPI, the decision to vaccinate a
specific district is made at the provincial
Centre for Preventive Medicine (CPM).
Once cholera cases are detected in a
district, the provincial CPM deliberates
whether or not to vaccinate against
cholera and to identify the age groups to
be vaccinated. This decision has to be
approved by the local provincial govern-
ment, who finances the deployment of
cholera vaccines at the local level.
Although provinces may request their
preferred number of doses of OCV,
procurement of vaccines is limited by the
amount allocated for EPI vaccines in the
national budget. If the number of OCV
doses allocated to the province is less than
the amount the province requested, then
provinces may request additional doses for
deployment the following year.
While the National EPI pays for the
purchase and shipping of OCVs, the
provincial CPM is responsible for plan-
ning and implementing the vaccine de-
ployment. Figure 3 shows the process,
from OCV requisition to deployment.
More recently, OCV procurement has
been limited, and vaccines have to be
procured for the following year. Requests
must be made by October to receive
vaccines the following year. Based on the
government’s current budget appropria-
tion to the National EPI, doses are
procured from Vabiotech, the manufac-
turer in Vietnam. This budget has grad-
ually been reduced and the doses procured
by the EPI have declined (Figure 2).
Vaccine Deployment
Since 1998, OCVs are provided just
prior to the expected cholera season, and
in Hue the cholera season is during the
months of May to November. Vaccines
are delivered to the provincial CPM, then
transported and stored at the district
Health Centre. On the day of the
campaign, vaccines are brought in cold
boxes to commune health stations where
vaccinations are conducted.
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Vaccinations are arranged similarly to
other mass campaigns. The vaccine is
administered in commune health centres
(CHC), where routine EPI vaccines are
also given. Community mobilization
consists of commune health workers
going to households and informing them
of the dates of vaccination and the need
for two doses to ensure protection.
During vaccination days, CHCs are open
from 8A.M. to 5P.M., and campaigns
usually last for two days, with one day
being on a Saturday or a Sunday in
order to allow for participation of those
who work during the weekdays. Vacci-
nation cards are provided to individuals
who are vaccinated and logbooks con-
taining the names of vaccine recipients
are maintained. Those who were vacci-
nated are advised to return for the
second round, scheduled two weeks later.
Commune health workers provide re-
minders prior to the second round to
ensure compliance with the schedule. If
families are unable to go to the CHCs,
commune health workers visit the resi-
dence to provide vaccines.
Reactive Vaccinations
Reactive campaigns with OCVs are
conducted once a cholera outbreak has
already begun. Reactive vaccinations were
conducted in Ca Mau city in 2001, in Hai
Phong and Kien Giang in 2003, and in
Hanoi in 2008. In Ca Mau, after three
cases of V. cholerae O1 Inaba were
identified, children attending two primary
schools located near waterways were vac-
cinated [7]. During these years, OCVs
were readily available from the National
EPI, which allowed the immediate imple-
mentation of a mass vaccination campaign.
More recently, during the Hanoi out-
break in 2007–2008, the Ministry of
Health directly purchased OCVs and,
together with NIHE, implemented a mass
vaccination campaign in two affected
districts located near waterways where
residents were assessed to have poor access
to clean water, hygiene, and sanitation.
The campaign included only individuals
older than ten years (who were not
pregnant) because the majority of the cases
in Hanoi were in people aged ten years and
older [10]. Organized by the Hanoi CPM
and held in CHCs, the campaign lasted for
three days per round. Vaccination cards
were distributed and records were kept.
Prior to the campaign, dissemination of
information through radio, television, and
commune health workers was conducted.
Since the campaign was held in the middle
of an ongoing outbreak, the interval
Figure 1. Map of average annual cholera incidence and oral cholera vaccine use, 1998–
2012. Years when oral cholera vaccines were used: An Giang (1998, 2000, 2001, 2004, 2005,
2011); Ben Tre (2000, 2001, 2002, 2011); Ca Mau (1998, 2000, 2003, 2004, 2005, 2006, 2011); Can
Tho (1999, 2000, 2002); Da Nang (2004, 2005); Dong Thap (2001, 2002, 2003); Kien Giang
(1999, 2000, 2001, 2003); Long An (2001); Quang Binh (2006); Quang Nam (2004, 2005, 2006,
2007); Quang Ngai (2004, 2005, 2006); Quang Tri (1999, 2000, 2001, 2004, 2005, 2006, 2007);
Hue (1998–2012); Tien Gian (2012); Hanoi (2008).
doi:10.1371/journal.pmed.1001712.g001
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between doses was only one week, instead
of the usual two weeks.
Monitoring of Vaccination
First and second dose recipients, vac-
cine coverage and wastage are reported to
the National EPI. Although an incident of
mass psychogenic illness among primary
school children occurred in Ca Mau City
in 2001 [9], no serious adverse events have
been reported with OCVs since 1998. The
small number of adverse events reported
with OCVs prior to 2002 may be partly
due to a weak adverse events following
immunization (AEFI) monitoring system
in Vietnam; however, improved AEFI
monitoring was initiated in 2002 and
expanded nationwide in 2008. A review
of the AEFI surveillance in 2009 found a
low rate of AEFI across the country [11].
Costs of Vaccination
In 1998, costs for the first cholera
vaccination in Hue City were calculated
at US$0.89 per fully vaccinated person,
and 79% of this amount was spent on
vaccines [12]. More recent estimates of
costs of vaccination were calculated from
the 2013 campaign in Hue. The National
EPI procured vaccine from the manufac-
turer at US$0.48 per dose (at 2012
exchange rate US$1 to VND 20,828)
[13] and program cost to distribute and
administer OCVs was US$0.11 per fully
vaccinated person. Thus, about US$1.07
was spent per person vaccinated and 90%
of this went to vaccine purchase. Because
mass campaigns are held yearly in Hue
and are part of the routine public health
provision, implementation required mini-
mal additional costs and are lower than
might be expected if not integrated into a
routine system. The program expenditures
included costs for transport boxes, ice
packs, printing of forms, vaccination cards,
logbooks, and posters, training, and hon-
oraria for the staff involved in the
vaccination campaign. In 2013, the cam-
paign immunized 46,398 two-dose vaccine
recipients from five communes and uti-
lized 130 health staff from the respective
communes at a cost of approximately
US$5,177. This amount did not include
other costs routinely covered by the
provincial EPI such as costs for social
mobilization and waste management.
Since cholera vaccination is now part of
the public health program in Hue, it is
difficult to attribute community health
workers’ visits for social mobilization and
for waste management separately.
Lessons Learnt
Vietnam has now delivered over 10
million doses of vaccine, and OCV use has
been associated with a substantial decline
in cholera in this country. Hue, a province
that has used OCVs annually since 1998,
has not reported any cholera cases since
the last outbreak in 2003. Furthermore,
quarterly environmental sampling of the
water from the Perfume River running
through Hue City has consistently been
negative for V. cholerae since 2005 (D. D.
Anh, personal communication, 22 January
2014). A factor influencing this decision to
use OCVs in Hue was the burgeoning
tourism sector; the local government of
Hue understood that cholera outbreaks
would hinder tourists from visiting their
province and felt that continued use of
OCVs, along with improvements in water
and sanitation, was important to their
cholera control effort.
While the absence of cholera may have
been affected by economic progress and
Figure 2. Incidence of cholera in Vietnam and number of vaccine doses procured through the National Expanded Programme on
Immunization, 1998–2012. Number of vaccine doses procured through the EPI does not include the additional approximately 400,00 doses
procured directly by the Ministry of Health for the 2008 mass campaign in Hanoi and the other doses for Long An and Vinh Long in 2001.
doi:10.1371/journal.pmed.1001712.g002
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improvements in water and sanitation
facilities in Hue, access to clean water
and sanitation in the province has not
been uniform. In 2009, a survey revealed
that only 37% of the surveyed individuals
in Hue had access to a centralized water
system, lower than the reported 52%.
Furthermore, this supply was intermittent
through the day, especially during times of
drought [14]. Nationwide, there are sub-
stantial differences among urban and rural
households. Of urban homes, 58% have
water piped in directly, while only 9% of
rural homes had piped water at home.
Access to improved sanitation increased
from 46% in 1995 to 75% in 2011.
Similarly, substantial gaps exist between
urban and rural homes, with 93% and
67% having access to improved sanitation
[15]. The Government of Vietnam and
international donors have spent more than
US$1 billion in improving water and
sanitation [16] and expect to spend more
money to address these gaps. There is no
doubt that water supply programs and
improved sanitation are advantageous for
long-term control of various diseases
including cholera; however, cost-benefit
analysis has shown that in certain situa-
tions, community-wide vaccination pro-
grams may be more equitable in the short
term [17].
The impact of OCVs is harder to assess
in other provinces because of the variabil-
ity in implementation. There was a
precipitous decline in the number of
cholera cases in 1997, even prior to
extensive usage of OCVs. The initial
decline may have been due to the cyclical
nature of the disease. However, this
decline was sustained, and apart from the
outbreaks in Hanoi and the northern
provinces in 2007, there were never more
than 1,000 reported cases nationwide,
annually. Furthermore, if the province
followed the recommended age for oral
cholera vaccination, which is two to five
years old, the number of doses deployed
would be lower. Recent studies have
shown that OCVs confer herd protection
provided that high enough coverage is
achieved. In Kolkata, coverage of at least
28% resulted in indirect protection. If only
two- to five-year-olds were vaccinated,
indirect protection would have been less
likely. In contrast, in Hue, where OCVs
are given to all non-pregnant individuals
older than one year, indirect protection of
the unvaccinated segment of the popula-
tion may explain the continued absence of
cholera despite the phased vaccination
that the province implements.
This assessment shows a temporal
association between the sustained decline
in cholera incidence and increased use of
OCVs. It does not aim, nor is it able to
show an overall causal relationship be-
tween OCV use and the general decline in
cholera cases. Cholera control in the
country may have been enhanced by
factors other than vaccination, including
implementation of public health control
measures and improvement of water and
sanitation infrastructure, as well as general
economic development. Instead, the expe-
rience in Vietnam shows how OCVs have
been used as an immediate measure
against cholera while appropriate infra-
structure is built, and how they have been
included as part of an integrated strategy
to control cholera.
Vietnam uses a ‘‘bottom-up’’ approach
in determining use of OCV. The provin-
cial CPM determines how many doses are
to be requested and how to deploy them.
Depending on the national budget and
the availability of vaccine, vaccine is
provided to the provinces. The vaccine
is then provided without cost to the
province, but the province must pay for
the cost of its distribution and adminis-
tration. This method facilitates local
decision making and places additional
responsibility on the local authorities to
evaluate their needs and to cover the
programmatic costs for vaccination. This
approach assumes that local authorities
have information on how best to deter-
mine if they need vaccine and how to
allocate it within the province.
A factor that may have affected the non-
deployment of OCVs, especially during
the 2007–2008 outbreaks, may be the
expenditures that provinces have to bear
in mounting vaccination campaigns. In
Hue, the incremental costs for mounting
the campaign may not be substantial;
however, in places that do not routinely
conduct mass cholera vaccination, the
costs may be higher. Since cholera cases
will more likely affect these less developed
Table 1. History of the development of oral cholera vaccine in Vietnam.
Date Events
1980s Encouraged by trial results in Bangladesh of a vaccine containing killed whole-cells of V. cholerae O1 with the cholera toxin B subunit [25,26],
scientists from the Vietnam National Institute of Hygiene and Epidemiology developed their own vaccine, following technology transfer from Sweden
[27]. The Vietnamese oral cholera vaccine was similar to the Swedish vaccine tested in Bangladesh, but did not contain the costly cholera toxin B
subunit.
1992 to 1993 An open field trial was conducted in Hue city and showed that two doses of this killed OCV was safe, immunogenic, and provided 66% protection
among individuals aged one year and older [28].
After 1992 Vietnamese scientists added V. cholerae O139 to the vaccine following reports of V. cholerae O139 outbreaks in India and Bangladesh. The resulting
bivalent vaccine was shown to be safe and immunogenic [29].
1997 The bivalent vaccine was used in a large field trial in the city of Nha Trang, enrolling approximately 300,000 residents [30]. However, no cases of
cholera were detected during the subsequent two years of follow-up precluding estimation of vaccine effectiveness (D. D. Anh, personal
communication, 22 January 2014).
1997 The bivalent OCV was locally licensed as ORC-Vax, produced in Vietnam by the Company for Vaccine and Biological Production No.1 (Vabiotech),
under the auspices of NIHE, and introduced in the country’s routine vaccination programme.
1998 A large-scale mass vaccination program involving non-pregnant residents aged two years and older was conducted in half of the communes of Hue
city. Intensive surveillance conducted for two years did not reveal any case of cholera.
2000 The remaining communes in Hue were vaccinated.
2003 A cholera outbreak occurred in Hue, allowing estimation of vaccine effectiveness. A case-control study estimated that the vaccine provided 50%
protection three to five years after vaccination [6]. This is the first study to suggest that a killed OCV may provide long-term protection.
2009 ORC-Vax was reformulated to comply with cGMP and international standards and was licensed as mORC-Vax.
doi:10.1371/journal.pmed.1001712.t001
PLOS Medicine | www.plosmedicine.org 5 September 2014 | Volume 11 | Issue 9 | e1001712
areas, allocations to support program costs
for OCV campaigns may be needed to
prevent cholera in these high-risk areas
since improvements in water and sanita-
tion will take time.
OCV continues to be used in Vietnam;
however, budgetary constraints have re-
sulted in fewer doses being procured by
the government, due to the perception of a
lower threat from cholera as well as other
competing priorities. As vaccines for other
diseases are being recommended, govern-
ments will prioritize which vaccines to
implement. With the need to prioritize,
cholera surveillance becomes increasingly
important to understand when and where
to implement future OCV campaigns.
Though endemic cholera has declined
in Vietnam, cholera may also spread from
other countries. The last large cholera
outbreak in Hanoi and other northern
provinces lasted for 20 months, affecting
more than 1,500 individuals in 22 cities
and provinces of northern Vietnam. Pa-
tient isolates from this outbreak were
similar to V. cholerae O1 isolates obtained
during the cholera outbreaks in Thailand
in January to October 2007 and in Laos in
December 2007 [18]. These isolates had
not been previously identified in Vietnam,
suggesting recent importation [19]. Vul-
nerability to such cholera outbreaks em-
phasizes the need for continued vigilance
by enhancing surveillance and improving
control.
Future Use of Oral Cholera
Vaccines
As the cholera incidence in Vietnam
decreases, the most affected age groups
will change. Adults and older children will
increasingly bear the brunt of the disease.
Indeed, in the 2007–2009 outbreak in
northern Vietnam, among 8,064 cases
only 4.6% of cholera cases were reported
among children aged more than five years.
Intensified disease surveillance should be
conducted to monitor these epidemiologic
changes to guide the government in future
policies as regards OCV use. Further-
more, as the economy of Vietnam
improves, initiatives toward cholera elim-
ination may be considered.
Since Vietnam is the only country that
has used OCVs extensively as part of an
overall national strategy to control chol-
era, the experience with this vaccine in
Vietnam may be useful for other areas
now considering its use. The revised
recommendations of the WHO encourag-
ing the use of OCV in endemic areas and
the decision by Global Alliance for
Vaccines and Immunization (GAVI) to
help support the use of OCVs should lead
to increased use of the vaccine. In July
2013, a global cholera vaccine stockpile
was developed as an additional tool for
cholera control. The vaccine currently
included in the stockpile is Shanchol,
an OCV very similar to mORC-Vax.
Shanchol was shown to be effective [20]
and feasible to use in various settings [21–
23], and models have shown that more
cases were prevented when used in
combination with Water, Sanitation, and
Hygiene (WASH) [24]. The global stock-
pile requires a reliable supply of OCV;
unfortunately, the OCV from Vietnam is
currently not WHO-prequalified and
therefore cannot be purchased by United
Nations agencies. However, the National
Regulatory Agencies (NRA) of other
countries at risk could license mORC-
Vax; and registration would allow use of
mORC-Vax in their countries. Vabiotech,
together with the Vietnamese NRA, is
working to have the vaccine prequalified.
This experience of Vietnam in deploying
a two-dose oral cholera vaccine for more
than 15 years indicates that the vaccine can
be feasibly used in public health settings.
Some of the lessons from Vietnam may
prove to be useful in other countries where
cholera remains a problem. The availability
of a vaccine that may be used, even during
an outbreak as part of an integrated strategy
provides hope in countries that continue to
battle the scourge of this disease.
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